AI assistant
Celularity Inc — Director's Dealing 2021
Jul 21, 2021
34506_dirs_2021-07-20_4fa02a9d-c0a3-40d5-9e87-84c8cf1f080a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: Celularity Inc (CELU)
CIK: 0001752828
Period of Report: 2021-07-16
Reporting Person: Brigido Stephen (Pres, Functional Regeneration)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-07-16 | Stock Option (Right to Buy) | $3.70 | A | 20379 | Acquired | 2031-07-16 | Class A Common Stock (20379) | Direct |
| 2021-07-16 | Stock Option (Right to Buy) | $3.70 | A | 153718 | Acquired | 2031-07-16 | Class A Common Stock (153718) | Direct |
| 2021-07-16 | Stock Option (Right to Buy) | $10.21 | A | 76859 | Acquired | 2031-07-16 | Class A Common Stock (76859) | Direct |
Footnotes
F1: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, December 15, 2019, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.
F2: Pursuant to the Merger Agreement and Plan of Merger and Reorganization, dated January 8, 2021 (the "Business Combination Agreement"), by and among GX Acquisition Corp. ("GX"), Alpha First Merger Sub Corp., Celularity LLC and Celularity Inc. ("Legacy Celularity"), each security to purchase shares of Legacy Celularity common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a 1-to-0.768594024295126 conversion ratio. Upon consummation of the business combination, GX changed its name to "Celularity Inc."
F3: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, August 30, 2019, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.
F4: This option is fully vested and exercisable.